News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

News


Pharmaceutical Technology Europe


News bites

Tablet sticking research

Research is being carried out by I Holland and the UK's University of Nottingham in an attempt to combat the problem of tablet sticking. The project, Tabletting Science Anti-stick Research, will use sticky excipients and APIs to analyse why one coating prevents sticking where another does not.
http://PharmTech.com/Sticking

FDA lawsuit dismissed

A US court has denied AstraZeneca's request for a preliminary injunction against FDA. AstraZeneca filed the lawsuit in March with regards to the antipsychotic medicines Seroquel (quetiapine fumarate) and Seroquel XR, seeking to prevent FDA from granting final marketing approval to a generic version of quetiapine until December 2012.
http://PharmTech.com/dismissed

GSK's biopharma boost

GlaxoSmithKline will build a new biopharmaceutical manufacturing facility in the UK — the first in the country in almost forty years. In addition, the company will invest approximately 600 million at other facilities in the UK to increase production of key APIs. The investments are one of the largest commitments to the UK life-sciences sector in recent years.
http://PharmTech.com/biopharmaboost

Ben Venue's review results

The EMA has recommended that manufacturing processes for two anticancer medicines be transferred from Ben Venue Laboratories to alternative facilities. The decision follows GMP shortcomings identified at the US-based manufacturer in late 2011, and marks the end of the EMA's review of medicines produced at the site.
http://PharmTech.com/benvenue


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here